EES-Web Receipt date: 09/29/2006

BARNES & THORNBURG LLP

10/594791 IAPO1 Rec'd PCT/PTO 29 SEP 2006

> 11 South Meridian Street Indianapolis, Indiana 46204 (317) 236-1313 (317) 231-7433 Fax

IN THE UNITED STATES PATENT OFFICE

Earliest Priority	2 April 2004 (02.04.2004)	Certificate Under 37 CFR 1.10
Date:		} Express Mail No.: <u>EV 417142613 US</u>
International	PCT/GB2005/001197	Date of Mailing: 29 September 2006
Serial No.:		1 hereby certify that this correspondence is being deposited with the United States Postal Service's
U.S. Serial No.:	Unknown	#Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date above and is addressed to the Commissioner for Patents, P.O. Box
Invention:	CANCER ASSOCIATED ANTIGENS	1450, Alexandria, VA. 22313-1450. (Signature)
Applicants:	REES, Robert Charles; MILES, Amanda Kathleen; LI, Geng	Ernest A. Carlson (Typed or Printed Name of Person Mailing Paper or Fee)
International Filing Date:	24 March 2005 (24.03.2005)	} }
Attornev	42133-200861	}

INFORMATION DISCLOSURE STATEMENT

Attn: DO/EO/US Mail Stop: PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket:

This statement is filed in the application identified above pursuant to 37 C.F.R. § 1.56. In accordance with 37 C.F.R. § 1.98(a)(2), no copies of the cited U.S. references are provided. A copy of each of the other references is provided for review by the Examiner.

No representation is intended that a complete search has been made of the prior art or that no better art references than those listed below are available. The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in §1.56(b).

EES-Web Receipt date: 09/29/2006

10/594791 LAPO1 Rec'd PCT/PTO 29 SEP 2006

Please charge any fees that might be due in connection with this Information Disclosure Statement to our Deposit Account No. 10-0435, using our reference number 42133-200861. A duplicate copy of this authorization is enclosed for that purpose.

Respectfully submitted,

Keyin L. McLaren Atty. Reg. No. 48351 Attorney for Applicants

KLM/ezc/838193 Indianapolis, Indiana 46204 (317) 231-7776 EFS-Web Receipt date: 09/29/2006

Sheet 1 40/594791

UNKNOWN

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

IAF	01 Rec d PCT/PTO 29	SEP 2006 Unknown
	APPLICANT REES, Robert Charles et al.	
	FILING DATE	GROUP

U.S. PATENT DOCUMENTS								
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
	AA							
FOREIGN PA	ATENT D	OCUMENTS						
		Document Number Date Country Class Subclass Translation Yes No					Translation Yes No	
/BD/ AB WO2001/053312 A1 7/26/2001 WO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
OTTLETTE	LITEITOL	transfer of the control of the contr	ato, r artificina r agos, i					
/BD/	ALI, Selman A., et al., "Tumor Regression Induced by Intratumor Therapy with a Disabled Infectious Single Cycle (DISC) Herpes Simplex Virus (HSV) Vector, DISC/HSV/Murine Granulocyte-Macrophage Colony-Stimulating Factor, Correlates with Antigen-Specific Adaptive Immunity," The Journal of Immunology, 2002, Vol. 168, pp. 3512-3519							
7700000	AD	CHEN, Yao-Tseng, et al., 'The National Academy of	CHEN, Yao-Tseng, et al., "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening," The National Academy of Sciences of the USA, 1997, Vol. 94, pp. 1914-1918					
	AE	GOEPEL, J.R., et al., "Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma," Br. J. Cancer, 1991, Vol. 64, pp. 880						
	AF	IAGER Dirk et al "Cano	er-Testis Antigens and	INGI Tumor Supressor Gene I	Product Are F	Rreast Cancer A	ntigens	
	<u> </u>			pts and a Homologue Gene," C				
8500000000	AG	JAGER, Elke, et al., "Induction of primary NY-ESO-1 immunity: CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers," PNAS, 2000, Vol. 97 No. 22, pp. 12198-12203						
	AH	JAGER, Elke, et al., "Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral cellular immune responses," PNAS, 2000, Vol. 97, No. 9, pp. 4760-4765						
888	ΑI	McINTYRE, Catherine A., et al., "Treatment of Malignant Melanoma and Renal Cell Carcinoma with Recombinant Human Interleukin-2: Analysis of Cytokine Levels in Sera and Culture Supernatants," Eu F. Cancer, 1992, Vol. 28, No. 1, pp 58-63						
	AJ	MIAN, Shahid, et al., "Immunogenicity of tumor associated antigens, Cancer Immunology," 2001, pp. 1-26						
	AJ	MIAN, Snanid, et al., Imin	tunogenicity of turnor a	issociated antigens, Cancer Imi	nunology, 2	001, pp. 1-26		
	AK	OLD, R. W., et al., "Princip	oles of Gene Manipulat	ion, An Introduction to Genetic	Engineering	," 5 th Edition, 1	994, Fig. 10.1	
	AL	SAHIN, Ugur, et al., "Human neoplasms elicit multiple specific immune responses in the autologous host," Proc. Natl. Acad. Sci. USA, 1995, Vol. 92, pp. 11810-11813						
	AM	SCANLAN Matthew Let	al "CHARACTERIZ	ATION OF HUMAN COLON	CANCER AT	NTIGENS REC	COGNIZED BY	
		AUTOLOGOUS ANTIBO	DIES," Int. J. Cancer,	998, Vol. 76, pp. 652-658	CANCLICA		COGNIZED DT	
980	AN	STOCKERT, E., et al., "A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens," J. Exp. Med., 1998, Vol., No. 8, pp. 1349-1354						
	AO	THOMSON Soom A -4-1	"D-1: £M-16:-1	CD0 Cddd T C II F i	-1 . DNIA 3/		1 1 6	
88000000	AU	THOMSON, Scott A., et al., "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," The Journal of Immunology, 1998, Vol. 160, pp. 1717-1723						
00,000	AP	TURECI, Ozlem, et al., "Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease," The Journal Of Biological Chemistry, 1997, Vol. 272, No. 10, pp. 6416-6422						
000000000000000000000000000000000000000	AQ	XP-001207011, MILES, Amanda, et al., "Immunology 8: Tumor Antigens, Expression analysis of prostate-associated tumor antigens identified via a modified SEREX approach," Proceedings of the American Association for Cancer Research, 2003, Vol. 44, 2 nd ed. pp. 358-359						
80	AR	XP-002336236, LEE, Sang	-Yull, et al., "Immunon	nic analysis of human sarcoma,	" PNAS, 200	3, Vol. 100, No	o. 5, pp. 2651-2656	
V	AS	XP-002336237, Lee, et al., "Table 3 Sarcoma/Testes antigens defined by serological analysis of cDNA expression libraries," Proc. Nat'l. Acad. Sci., 2003, Vol. 10, 0437972100					ssion libraries," Proc.	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.								
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

EFSeweb Receipt date: 09/29/2006

. She 10/5 94791

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

- Onca or					
PANUFARES O PCT/PTO	29 SEP 2006				
42133-200861	Unknown				
APPLICANT REES, Robert Charles et al.					
FILING DATE	GROUP				
Herewith	UNKNOWN				

U.S. PATENT DOCUMENTS								
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
	ВА							
FOREIGN PA	TENT D	OCUMENTS T		-	T	T		
		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	вв							
OTHER REF	ERENCE	S (Including Author, Title, D.	ate, Pertinent Pages,	Etc.)				
/BC/	/BC/ BC Xu 0.03336340, LGE, S. Y., stell 1 reserves Ma. AM214015, Wheneverpiers occurred extigen NSC S.1.9. 37 mOM 1, partial odd?							
000000000000000000000000000000000000000	BD	VD 003336341; OTA, Tystely 4ccession No. 44004192; "Homo cepiens eDNA FLUI0330 for elene NT2DM3009624 weekly pinnibute splicing factor, 4RGN IND/SERMICAL4"						
	BE	\{P\-092336202;\P\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	XP 002336202; PANC, V.T., et al., Accession No. AA139197, Human polynucleonae SEQ. ID. NO. 1400"					
	BF	XP-002336283, TANG. Y.	T ACCESSION NO. AAI	vi40041, 11uman polypeptide 8	PO-IB-NO-	oilyk (Afrikaanaa		
	BG	**************************************	- Singentiin 4.0000 Singentifette	··^*/*!•••••••••••••••••••••••••••••••••••	N F 2399 pot y	peptide sequer	100 SEQ. 119: 140: 4798"	
	вн	- NP-002326286; OT-4; T-y-ot-al-y-4-coccoion No4-X876100; "Sequence-1-1-101-from Patent-BR1074617"						
	BI	M-005336587; SUGAHA	Myinginetotlindeteessieu	No. ADI26865, HImmorprotei	in that promo	es STAT6 acti	apopopi ja gapalija je kirkonomomo	
*	Bl ,		in et al.; recession No.	-BD587825; "STATe activating	- Beithigum			
	вк							
								
	BL	<u> </u>						
	ВМ				•			
	BN							
	ВО	 						
	BP							
	ВQ							
	BR	 						
	D.C.							
	BS							
	вт							
		/Brad Du	.64(06/06/2008	
		reference considered, whether	er or not citation is in co	onformance with MPEP 609.	mmunication	to applicant		